StemCell Therapy

umbilical cord blood | Cord Blood - Life Saving Out of the Womb
http://www.cordbloodrecommendation.com The collected blood should be processed by specialists in the laboratory within 48 hours and stored properly. Stems cells are very important. Again, these are not hard and fast numbers but just estimates. This procedure also supplies a rapid chromosome analysis within high levels of accuracy. As we all know that it is rich in Hematopoietic stem cells. Extracting bone marrow is a very painful and difficult procedure, and if you have your own blood, then you do not need to make your family members go through the bone marrow transplant procedure. If your child is able to pass the pre-screening process, the program has been highly regarded and is an excellent, free alternative to private registry. Preserved stem cells are used when the body is in a weakened state from disease or treatments such as chemotherapy. Cord blood stem cell therapy has regenerative characteristics. This kind of disease typically attacks the neurons of the central nervous system in the brain. If they decide to donate to a public facility, there are no storage fees however because of privacy concerns all identification features are removed from that particular storage lot within a few years. How many years can a baby #39;s cord blood be saved?Cord blood banking is a relatively new concept. If they are able to grow sufficiently, the new cell will make new blood cells. If you have stem cells of your child, then you will not even need to find bone marrow donors in case your child isFrom:Implantes DentalesViews:0 0ratingsTime:01:18More inScience Technology

Link:
umbilical cord blood | Cord Blood - Life Saving Out of the Womb - Video

stem cell therapy @ kapuso jessica soho
LAMININE It #39;s not often that the perfect super-supplement with the perfect story comes around, but the story of Laminine is far from a mythical tale. As far back as 1929, a Medical Doctor in Canada discovered a way to extract the #39;life-essence #39; of a nine day old fertilized avian egg. Through research, it was found that on exactly the ninth day, all the ingredients necessary to create life are at its #39; highest level. In fact, the life-giving proteins are so potent at this stage that a live chick is hatched a mere two weeks thereafter. This method of extraction and freeze-drying processes proved to be a historical monumental success for this Medical Doctor #39;s patients. 09333737867 for infoFrom:xpalfredViews:1 1ratingsTime:12:00More inHowto Style

Link:
stem cell therapy @ kapuso jessica soho - Video

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Go here to read the rest:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Charles - USA Stem Cells Testimonial
If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.From:USAStemcellsViews:4 0ratingsTime:10:04More inScience Technology

Originally posted here:
Charles - USA Stem Cells Testimonial - Video

Progenitor Cell Therapy For Neurological Injury
ll4.me Progenitor Cell Therapy For Neurological Injury Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4. Neural Stem Cells-Endogenous Repair of Neurological Injury.- Chapter 5. Traumatic Brain Injury: Pathophysiology and Models.- Chapter 6. Traumatic Brain Injury: Relationship of Clinical Injury to Progenitor Cell Therapeutics.- Chapter 7. Cell-Based Therapy for Stroke.- Chapter 8. Spinal Cord Injury: Pathophysiology and Progenitor Cell Therapy.- Chapter 9. Current Status of Clinical Trials using Progenitor Cells for Neurological Injury EAN/ISBN : 9781607619659 Publisher(s): Springer, Berlin, Springer Science Business Media Discussed keywords: Neurologie, Zelltherapie Format: ePub/PDF Author(s): Cox, Charles S. Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4From:dorethacopeland98549Views:0 0ratingsTime:00:14More inPeople Blogs

Go here to see the original:
Progenitor Cell Therapy For Neurological Injury - Video

SHIMMIAN MANILA - Celebs share good effects of stem cell therapy
From:myrenovatiosolutionsViews:1 0ratingsTime:01:30More inEntertainment

See the original post:
SHIMMIAN MANILA - Celebs share good effects of stem cell therapy - Video

PRP Vs Stem Cell Therapy
PRP Therapy Vs Stem Cell TherapyFrom:MiamiFootSurgeryViews:5 0ratingsTime:01:23More inHowto Style

More here:
PRP Vs Stem Cell Therapy - Video

Govt. Appoints Task Force To Explore Stem Cell Research
Minister of Health Hon. Dr. Perry Gomez announced that the government has appointed a 10 member task force, charged with making recommendations to the government to explore stem cell therapy in The Bahamas.From:ZNSNetworkViews:27 0ratingsTime:03:27More inNews Politics

See the rest here:
Govt. Appoints Task Force To Explore Stem Cell Research - Video

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:8 0ratingsTime:09:00More inPeople Blogs

Read the rest here:
PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video

PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:7 0ratingsTime:08:01More inPeople Blogs

See the rest here:
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video

CombiCult® Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult®) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult® is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:1 0ratingsTime:06:40More inScience Technology

See the rest here:
CombiCult® Workflow - Video

123Triad : wwmsbiologicscom
123Triad is proud to design website for http://www.wwmsbiologics.com WorldWide Medical Services Inc. is a company that for more than 10 years is dedicated to utilizing the most innovative technologies to provide its clients with the highest quality services. Worldwide Medical Services specializes in the Intra-operative treatment of surgical patients. One of their most exciting new products is platelet gel and adult stem cell therapy services which can be provided in a hospital or office setting. their Autotransfusion service is available 24/7 on a scheduled or emergency basis.From:123triadcoViews:1 0ratingsTime:00:36More inScience Technology

Continue reading here:
123Triad : wwmsbiologicscom - Video

blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com Umbilical cord blood is stored immediately after delivery, when the cord is cut. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. Scientists have found that umbilical blood can actually help to treat many types of medical issues. To make a long story short, the Adult Stem Cells did the trick. This would be a significant event, which would save thousands of lives of those waiting for an organ. Why would someone opt for cord blood preservation? Well, research is continually being conducted and cells extracted from this blood has already been used to treat and cure injuries and diseases. Cord Blood Banking facilities are places where you can bank your child #39;s cord blood and use it later on in life to cure life-threatening diseases. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Because of this amazing capacity of blood cells, they have been, still are and will continue to be used more and more to save lives and cure a number of diseases. ""Umbilical cord blood contains blood-forming cells that can be used to treat life-threatening diseases and conditions. Stem cells, researchers discovered, could cure many diseases such as leukemia and ...From:hotelesenMelgarViews:0 0ratingsTime:01:18More inScience Technology

Read the rest here:
blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Stem Cell Research and TNG
How close is Science to providing visors for the blind? Or what about curing blindness? Have you watched the episode "The Masterpiece Society" from season 5 of TNG? Cause I have a couple of philosophical things to say about that! An article about STEM CELL therapy in regards to vision impairment: abcnews.go.com Interview with TrekMate: http://www.trekmate.org.uk ***I feel like the Star Trek community is a lot bigger then what YouTube has to offer, so I #39;ve started uploading my own videos. A lot of you will find this painfully dorky -and it is- which is why constructive criticism is welcomed. For anyone who does like my posts, thank you! It would be nice to gather a little Trekkie community :)***From:ThatTrekkieGirlViews:6 1ratingsTime:06:51More inPeople Blogs

Go here to read the rest:
Stem Cell Research and TNG - Video

Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are cells which have the potential to develop into virtually any cells of the body. The characteristics of stem cells render them great possibility in treating illness as well as health rejuvenation. Stem cells can repair and renew damaged cells as well as replace the dead ones so that a damaged organ or tissue can be healed to its healthy state. Visit Stem Cell Malaysia at http:/stemcellmalaysia.com/ for more information on stem cells and stem cell therapy.From:stemcells2012Views:1 1ratingsTime:06:33More inHowto Style

More:
Stem Cells | Stem Cell Malaysia - Video

Thelma before Stem Cell Therapy
From:krazykp12Views:2 0ratingsTime:01:33More inPeople Blogs

Read this article:
Thelma before Stem Cell Therapy - Video

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.

THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday.

The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained.

Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale closed a week later.

"The formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient," Pluristem said in a press release.

THE BIG PICTURE: Pluristem said that three patients have been treated with PLX on a compassionate basis including the Romanian girl and two have died. The company said it believes the patients lived longer than expected following treatment, which demonstrates that PLX therapy can be effective. The company is studying the stem cells as a treatment for peripheral artery disease, nerve pain, and other conditions.

THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent, to $3.24 on Friday. The stock reached an annual high of $5 per share in August, and including Friday's gains, the shares are down 29 percent since the company announced the stock offering.

Go here to read the rest:
Pluristem shares bounce back after Thursday plunge

Washington, November 7 (ANI): Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat.

No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL.

"The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study," he stated.

The trial - called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy - was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced - about one million for each patient - Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

The researchers reported that in the 20 patients receiving CSCs, LVEF increased from 29 percent to 36 percent at four months following infusion. None of the 13 control patients in the trial received CSCs and this group showed, on average, no improvement.

The beneficial effect of the CSCs persisted and became progressively greater at the one- and two-year mark following infusion. At the one-year mark following infusion, LVEF increased by 8.1 percent, and at the two-year mark, by 12.9 percent.

View original post here:
Stem cell therapy improves heart function 2 years after heart attack

Published on 10 November 2012 Hits: 52 Written by Jovee Marie N. Dela Cruz

The Department of Health (DOH) on Friday said that it has become necessary to issue regulations for stem cell therapy in the country. Health Secretary Enrique Ona said that guidelines for clinics offering stem cell therapy will be released immediately by the DOH and the Food and Drug Administration.

We will issue guidelines because here in the country we dont know where the stem cell offered by clinics come from, he said.

According to the DOH, stem cell therapy belongs to the category of advanced cell therapy, which includes biologics and blood. Many countries apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy.

In many countries, stem cell is considered an investigational intervention, Ona said.

The DOH said that stem cell research employs both autologous (from same person) or allogenic (from another organism like an animal or another human cell or tissue sample) method.

Ona said that because there are many steps in the preparation of this lab and invasive procedure, there is a need to have a regulatory framework to protect Filipino citizens.

Continued here:
DOH to regulate stem cell therapy in PH

April Flowers for redOrbit.com Your Universe Online

Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients.

The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects.

Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session.

The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans.

The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient, said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study.

In all patients, cells with high regenerative reserve were obtained and employed therapeutically, said Anversa, professor of Anesthesia and Medicine at Brigham and Womens Hospital and Harvard Medical School. Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results.

The Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, or SCIPIO, trial was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower. A normal LVEF reading is 50 percent or higher.

The CSCs, referred to as c-kit positive cells because they express the c-kit protein on their surface, were harvested from 33 patients during coronary artery bypass surgery. The stem cells were then purified and processed so that they could multiply, and once an adequate number was produced about one million for each patient they were reintroduced into the region of the patients heart that suffered scarring during the heart attack.

At four months after infusion, the researchers report that LVEF increased from 29 percent to 36 percent for 200 patients. On average, the 13 control patients who did not receive a CSC infusion showed any improvement.

Visit link:
Studies On Stem Cell Therapy After Heart Attack Show Mixed Results